

1-12-2023

Long-term hematologic improvement in a patient with cytopenic myelofibrosis treated with pacritinib

Abdulraheem Yacoub
University of Kansas

Ruben A Mesa
University of Texas Health Science - San Antonio

Stephen T Oh
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4



Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Recommended Citation

Yacoub, Abdulraheem; Mesa, Ruben A; and Oh, Stephen T, "Long-term hematologic improvement in a patient with cytopenic myelofibrosis treated with pacritinib." *JCO Precision Oncology*. 7, e2200523 (2023).
https://digitalcommons.wustl.edu/oa_4/1299

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib

Abdulraheem Yacoub, MD¹; Ruben A. Mesa, MD²; and Stephen T. Oh, MD, PhD³

JCO Precis Oncol 7:e2200523. © 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License 

Introduction

Cytopenic myelofibrosis (MF) is associated with poor prognosis and poses a therapeutic challenge because of limited treatment options. Co-occurrence of anemia and thrombocytopenia is common in MF, with at least two thirds of patients developing both.¹⁻³ Progressive anemia generally requires RBC transfusion,⁴ which is associated with inferior quality of life.^{5,6} Similarly, thrombocytopenia is associated with worse symptoms³ and higher rates of leukemia and death.⁷ Previously approved JAK1/2 inhibitors are of limited use in cytopenic patients because of treatment-related myelosuppression⁸⁻¹⁰ in contrast to the recently approved JAK2-specific inhibitor pacritinib. Pacritinib has been associated with less myelosuppression and hematologic improvement,^{1,11,12} possibly related to its unique kinome profile as an inhibitor of two inflammatory mediators, interleukin-1 receptor–associated kinase 1 (IRAK1), and activin receptor-like kinase 2, also known as activin A receptor type 1 (ACVR1).^{13,14}

Pacritinib has been studied in multiple phase 2 and 3 MF trials, with a focus on spleen and symptom benefit rather than hematologic improvement and long-term outcomes.^{11,12,15} Here, we report a case of a patient with MF and profound cytopenias who had ongoing hematologic improvement and symptom benefit over 4 years of pacritinib therapy.

Consent

The patient has provided written informed consent for the submission and publication of this clinical case report.

Case Report

This patient, now a 72-year-old woman, presented with symptomatic anemia (hemoglobin 8.9 g/dL) and thrombocytopenia (platelet count $27 \times 10^9/L$) in 2009 and was diagnosed with primary MF with a *JAK2*^{V617F} mutation. Medical history included well-controlled hypothyroidism and gastroesophageal reflux disease. Her MF was initially managed with supportive care, including erythropoiesis-stimulating agents, but in 2017, she experienced worsening disease with progressive

anemia. The patient was unable to maintain a hemoglobin of 7 g/dL without frequent transfusion and was subsequently managed with transfusions every 2 weeks to maintain hemoglobin > 6 g/dL. As the cytopenias worsened, anemia restricted daily activities, and thrombocytopenia resulted in spontaneous, profuse bruising. Progressive, symptomatic splenomegaly and weight loss were reported. The patient declined allogeneic stem-cell transplantation because of the mortality risk. Instead, she enrolled in a clinical trial with the anti-CD123 antibody tagraxofusp, which was discontinued after 3 months because of lack of benefit. In March 2018, ruxolitinib was started at 5 mg daily (standard dose: 20 mg twice a day) but discontinued within 6 weeks because of worsening cytopenias and a gastrointestinal bleeding event.

In May 2018, the patient was enrolled in a dose-finding study¹⁵ of the JAK2/IRAK1/ACVR1 inhibitor pacritinib. At this time, the DIPSS-Plus score showed high-risk disease with a median overall survival projected at 1.3 years.¹⁶ In screening, there was bilateral lower extremity petechiae and massive splenomegaly palpable 25 cm below the costal margin. Laboratory tests revealed pancytopenia (WBCs $1.4 \times 10^9/L$, hemoglobin 7.7 g/dL, platelets $31 \times 10^9/L$). Bone marrow biopsy showed 50% cellularity, grade 3 fibrosis, 3% blasts, normal karyotype, and a high-risk mutational profile including pathological mutations in *JAK2* (variant allele frequency [VAF] 6.2%), *NRAS* (VAF 26%), *GNAS* (VAF 13%), and *ASXL1* (VAF 48%). The patient was randomly assigned to intermediate-dose pacritinib (100 mg twice a day) and continued until the study concluded in July 2019, after which pacritinib was administered under a compassionate use program with a subsequent transfer to commercially available drug after US Food and Drug Administration approval of pacritinib. When transitioning to compassionate use, her dose was briefly increased to 200 mg twice a day but was de-escalated to 100 mg twice a day because of gastrointestinal side effects.

Over a 4-year treatment course with pacritinib, the patient has experienced a marked improvement in

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on November 21, 2022 and published at ascopubs.org/journal/po on January 12, 2023; DOI <https://doi.org/10.1200/P0.22.00523>




FIG 1. Blood counts over time. (A) Hemoglobin levels over time (2017-2022). (B) Platelets counts over time (2017-2022). (C) WBC over time (2017-2022).

anemia. A blood transfusion has only been required once since the start of therapy, with the hemoglobin consistently > 9 g/dL since December 2020, peaking at 11.6 g/dL (Fig 1A). The platelet count initially remained stable but rose dramatically after 2 years and has been consistently > 50 × 10⁹/L since that time (Fig 1B), correlating with resolution of petechiae and ecchymoses. A similar trend was observed with WBCs, which increased because of resolving neutropenia (Fig 1C). During the first 24 weeks of pacritinib therapy on study, she had 22% spleen volume reduction and reported symptom improvement. A repeat bone marrow biopsy after 4 years of therapy showed no evidence of disease progression, 80% cellularity, grade 2 fibrosis, 1% blasts, normal karyotype, and numerically stable/decreasing pathological mutations in *JAK2* (VAF 4.7%), *NRAS* (VAF 28%), *GNAS* (VAF 5%), and *ASXL1* (VAF 43%). Over her subsequent visits, she has reported improved appetite and decreased early satiety (including a desired 9-pound weight gain), as well as increased energy and ability to engage in daily activities and travel with family. She did not experience treatment-emergent gastrointestinal adverse events.

Discussion

This case highlights a patient with cytopenic MF who experienced dramatic improvement in all hematologic parameters while on long-term treatment with the novel JAK2 inhibitor pacritinib. Despite high clinical and molecular risk, the patient has had no evidence of pathological or molecular progression after 4 years of follow-up. The fact that these benefits occurred in conjunction with only a modest reduction in spleen volume suggests that splenic sequestration was not the major driver of this patient's cytopenias and that other features of pacritinib's inhibitory profile may have overcome the expected JAK2 class effect on anemia and

thrombocytopenia. As a JAK2-selective inhibitor, pacritinib avoids the pitfalls of JAK1 inhibition on megakaryocyte maturation and platelet production.^{1,17} Furthermore, it is possible that this patient's increase in hemoglobin was related to pacritinib's inhibition of ACVR1 and IRAK1.

Hepcidin is a peptide hormone that acts as a regulator of iron homeostasis and is elevated in patients with MF.¹⁴ Pacritinib is a potent inhibitor of the key hepcidin regulator, ACVR1.¹³ It has been postulated that ACVR1 inhibition reduces hepcidin, increasing iron availability for erythropoiesis.¹⁸ Additionally, pacritinib inhibits IRAK1, a serine/threonine kinase that mediates signaling from toll-like receptors and interleukin-1.¹⁷ Signaling from these pathways converge on NFκB, a transcription factor that regulates interleukin-6, the main cytokine implicated in stimulating hepcidin expression.^{17,19}

Although this patient continues to benefit from pacritinib 100 mg twice a day, it is possible that optimal spleen response would have also been achieved had the patient tolerated 200 mg twice a day, which is the recommended starting dose for all patients regardless of baseline platelet count. This report illustrates that hematologic benefit can be attained in patients necessitating dose reduction.

In conclusion, patients with cytopenic MF are commonly intolerant of the recommended doses of JAK inhibitors because of cytopenias, leading to suboptimal response. In the case presented here, long-term pacritinib treatment improved hematologic parameters and, as a result, quality of life. These benefits may be related to pacritinib's unique mechanism of action as a JAK2/IRAK1/ACVR1 inhibitor. Ongoing work is underway by a number of groups to further delineate the role of IRAK1 and ACVR1 inhibition in MF.

AFFILIATIONS

¹The University of Kansas Cancer Center, Westwood, KS

²UT Health San Antonio Cancer Center, San Antonio, TX

³Washington University School of Medicine, St Louis, MO

CORRESPONDING AUTHOR

Abdulraheem Yacoub, MD, Hematologic Malignancies and Cellular Therapeutics, University of Kansas Center for Bioinformatics, 14913 Delmar St, Overland Park, KS 66224-9543; e-mail: abdulraheemmd@hotmail.com.

AUTHOR CONTRIBUTIONS

Conception and design: Abdulraheem Yacoub, Ruben A. Mesa

Collection and assembly of data: Abdulraheem Yacoub, Ruben A. Mesa

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

Abdulraheem Yacoub

Consulting or Advisory Role: Incyte, CTI BioPharma Corp, Pharmaessentia, Pfizer, Novartis, Gilead Sciences, Acceleron Pharma, Servier, Notab, AbbVie

Ruben A. Mesa

Consulting or Advisory Role: CTI BioPharma Corp, Novartis, Sierra Oncology/GSK, La Jolla Pharma, Constellation Pharmaceuticals

Research Funding: Incyte (Inst), Genentech (Inst), CTI (Inst), Promedior (Inst), Celgene (Inst), AbbVie (Inst), Samus (Inst), Constellation Pharmaceuticals (Inst), Mays Cancer Center (Inst), NCI (Inst)

Stephen T. Oh

This author is an Associate Editor for *JCO Precision Oncology*. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Incyte, Blueprint Medicines, CTI BioPharma Corp, PharmaEssentia, Disc Medicine, Constellation Pharmaceuticals, Bristol Myers Squibb/Celgene, Geron, AbbVie, Sierra Oncology/GSK

Research Funding: Incyte (Inst), CTI (Inst), Kartos Therapeutics (Inst), Sierra Oncology (Inst), Blueprint Medicines (Inst), Constellation

Pharmaceuticals (Inst), Actuate Therapeutics (Inst), Bristol Myers Squibb/Celgene (Inst), Takeda (Inst), Sierra Oncology/GSK

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

This case report received editorial assistance by CTI BioPharma.

REFERENCES

- Sastow D, Mascarenhas J, Tremblay D: Thrombocytopenia in patients with myelofibrosis: Pathogenesis, prevalence, prognostic impact, and treatment. *Clin Lymphoma Myeloma Leuk* 22:e507-e520, 2022
- Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, et al: Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. *Br J Haematol* 181:397-400, 2018
- Scotch AH, Kosiorek H, Scherber R, et al: Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. *Leuk Res* 63:34-40, 2017
- Naymagon L, Mascarenhas J: Myelofibrosis-related anemia: Current and emerging therapeutic strategies. *Hemasphere* 1:e1, 2017
- Elena C, Passamonti F, Rumi E, et al: Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. *Haematologica* 96:167-170, 2011
- Tefferi A: Primary myelofibrosis: 2014 Update on diagnosis, risk-stratification, and management. *Am J Hematol* 89:915-925, 2014
- Masarova L, Alhurajji A, Bose P, et al: Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. *Eur J Haematol* 100:257-263, 2018
- Loscocco GG, Vannucchi AM: Role of JAK inhibitors in myeloproliferative neoplasms: Current point of view and perspectives. *Int J Hematol* 115:626-644, 2022
- Kuykendall AT, Komrokji RS: JAK Be Nimble: Reviewing the development of JAK inhibitors and JAK inhibitor combinations for special populations of patients with myelofibrosis. *J Immunother Precis Oncol* 4:129-141, 2021
- Venugopal S, Mascarenhas J: The Odyssey of pacritinib in myelofibrosis. *Blood Adv* 6:4905-4913, 2022
- Mesa RA, Vannucchi AM, Mead A, et al: Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. *Lancet Haematol* 4:e225-e236, 2017
- Mascarenhas J, Hoffman R, Talpaz M, et al: Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. *JAMA Oncol* 4:652-659, 2018
- Oh S, Mesa R, Harrison C, et al: MPN-145 retrospective analysis of anemia benefit of pacritinib from the PERSIST-2 trial. *Clin Lymphoma Myeloma Leuk* 22:S327, 2022
- Zhou A, Kong T, Fowles JS, et al: Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. *Br J Haematol* 197:e49-e52, 2022
- Gerds AT, Savona MR, Scott BL, et al: Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. *Blood Adv* 4:5825-5835, 2020
- Gangat N, Caramazza D, Vaidya R, et al: DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol* 29:392-397, 2011
- Singer JW, Fleischman A, Al-Fayoumi S, et al: Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. *Oncotarget* 9:33416-33439, 2018
- Asshoff M, Petzer V, Warr MR, et al: Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. *Blood* 129:1823-1830, 2017
- Andrews NC: Anemia of inflammation: The cytokine-hepcidin link. *J Clin Invest* 113:1251-1253, 2004

